,
Pharma Regulatory Services in Hungary – Overview
Hungary operates within the EU pharmaceutical regulatory framework, with the National Institute of Pharmacy and Nutrition (OGYÉI) acting as the national competent authority. While marketing authorizations are granted through EU-wide or coordinated procedures, sponsors must manage Hungary-specific administrative, linguistic, and post-authorization requirements to ensure timely approval, launch, and ongoing compliance.
Hungary may be included in Centralized, Decentralized, or Mutual Recognition Procedures, or may serve as a market for a national authorization where applicable. Effective engagement with OGYÉI, proactive national phase planning, and accurate implementation of EU decisions are critical to avoiding delays and ensuring approvals in the shortest time possible.
Freyr supports sponsors in executing Hungary-specific regulatory activities within broader EU strategies, ensuring national requirements are addressed efficiently across the product lifecycle.
Authorization pathways in Hungary
- Centralized Procedure (CP):
EU/EEA-wide authorization granted via EMA and the European Commission, with automatic applicability in Hungary, subject to national implementation activities. - Decentralized Procedure (DCP):
First-time approvals across multiple Member States, with Hungary participating as a Reference or Concerned Member State. - Mutual Recognition Procedure (MRP):
Extension of an existing national authorization to Hungary through coordinated recognition. - National Procedure (NP):
Single-country authorization administered by OGYÉI for products outside EU-wide or multi-state strategies.
Freyr Expertise – Pharma Regulatory Services in Hungary
- eCTD authoring, compilation, publishing, technical validation, and submission for CP, DCP/MRP, and Hungary national routes, including variations, renewals, and line extensions.
- Hungary-specific route-to-market execution, including RMS/CMS coordination, national phase planning, and alignment with OGYÉI procedural expectations.
- Clinical trial regulatory support under EU CTR, including CTIS submissions, ethics committee coordination, RFI management, and site activation support.
- National Module 1 authoring for Hungary, including administrative forms, declarations, fee coordination, and authority correspondence with OGYÉI.
- Product information and labeling management, including QRD-compliant SmPC, PL, and labeling texts, Hungarian translations, blue box content, Braille requirements, and mock-up coordination.
- Pharmacovigilance and safety operations for Hungary, including local PV contact support, RMP maintenance, PSUR/PBRER coordination, and implementation of EU safety decisions at the national level.
- CMC and quality support, including GMP/GDP readiness, dossier optimization, and coordination of manufacturing and distribution-related regulatory requirements.
- Lifecycle management covering variations, renewals, labeling updates, MA transfers, and national implementation of EU regulatory changes to ensure uninterrupted supply.
Post-approval and lifecycle management support
All authorization routes in Hungary operate under EU pharmacovigilance, quality, and safety frameworks, with national oversight by OGYÉI. Ongoing obligations include safety reporting, implementation of approved variations, maintenance of product information, and renewal management.
Freyr supports continuous compliance in Hungary by coordinating national lifecycle activities within broader EU and multi-country strategies, ensuring regulatory changes are implemented efficiently and without disruption to the market.
Engaging with Freyr enables efficient market entry, strong national phase execution, and sustained regulatory compliance in Hungary as part of EU and regional launch strategies.
Are you ready to launch your portfolios in Hungary?